ScholarIQanswers from OpenAlex & ORCID
Richard M. Sherry
ResearcherPublications, citations & collaboration network
Richard M. Sherry is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Richard M. Sherry have?
ScholarIQindexed works
Richard M. Sherry has 202 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard M. Sherry have?
ScholarIQcitation count
Richard M. Sherry has 42,148 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Richard M. Sherry?
ScholarIQh-index
Richard M. Sherry has an h-index of 60 in OpenAlex.
What is the i10-index of Richard M. Sherry?
ScholarIQi10-index
Richard M. Sherry has an i10-index of 94 in OpenAlex.
What is the ORCID of Richard M. Sherry?
ScholarIQorcid
The ORCID for Richard M. Sherry is on the source record.
What is the OpenAlex record for Richard M. Sherry?
ScholarIQopenalex
The OpenAlex for Richard M. Sherry is on the source record.
What are the most-cited papers on Richard M. Sherry?
ScholarIQmost cited works
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins, James Chih‐Hsin Yang, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Richard M. Sherry, Nicholas P. Restifo, Amy M. Hubicki, Michael R. Robinson, Mark Raffeld, Paul H. Duray, Claudia A. Seipp, Linda Rogers-Freezer, Kathleen E. Morton, Sharon Mavroukakis, Donald E. White, Steven A. Rosenberg
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Seth M. Steinberg, Helen X. Chen, Steven A. Rosenberg
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. Hughes, James Chih‐Hsin Yang, Richard M. Sherry, Richard E. Royal, Suzanne L. Topalian, Udai S. Kammula, Nicholas P. Restifo, Zhili Zheng, Azam Nahvi, Christiaan R. de Vries, Linda Rogers-Freezer, Sharon Mavroukakis, Steven A. Rosenberg
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg, James Chih‐Hsin Yang, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Giao Q. Phan, Deborah E. Citrin, Nicholas P. Restifo, Paul F. Robbins, John R. Wunderlich, Kathleen E. Morton, Carolyn M. Laurençot, Seth M. Steinberg, Donald E. White, Mark E. Dudley
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Mark E. Dudley, John R. Wunderlich, James Chih‐Hsin Yang, Richard M. Sherry, Suzanne L. Topalian, Nicholas P. Restifo, Richard E. Royal, Udai S. Kammula, D E White, Sharon Mavroukakis, Linda Rogers, Gerald Gracia, Stephanie A. Jones, David P. Mangiameli, Michelle M. Pelletier, Juan Gea‐Banacloche, Michael R. Robinson, David M. Berman, Armando Filie, Andrea Abati, Steven A. Rosenberg